Celsus Therapeutics Provides Update on MRX-6 from FDA Pre-IND Meeting

NEW YORK AND LONDON Celsus Therapeutics Plc (NASDAQ:CLTX), an emerging growth, development-stage biotech company, announced today that it held a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) on February 12th, 2014, to discuss the regulatory pathway for the development of MRX-6 cream in atopic dermatitis, also known as eczema, an inflammatory skin disorder affecting 5% to 20% of children world-wide. The Company plans to file the IND for MRX-6 with the FDA in the fourth quarter of 2014, and initiate Phase II trials in the US in the first half of 2015. Click here for the full press release

The release as fetched from its publisher. akaritx.com ↗